Abstract:Induced pluripotent stem cell (iPSC) technology, i.e. reprogramming somatic cells into pluripotent cells that closely resemble embryonic stem cells (ESCs) by introduction of defined transcription factors (TFs), holds great potential in biomedical research and regenerative medicine (Takahashi and Yamanaka, 2006Takahashi K. Yamanaka S. Cell. 2006; 126: 663-676Abstract Full Text Full Text PDF PubMed Scopus (16971) Google Scholar, Takahashi et al., 2007Takahashi K. Tanabe K. Ohnuki M. Narita M. Ichisaka T. Tomoda K. Yamanaka S. Cell. 2007; 131: 861-872Abstract Full Text Full Text PDF PubMed Scopus (13481) Google Scholar, Yu et al., 2007Yu J. Vodyanik M.A. Smuga-Otto K. Antosiewicz-Bourget J. Frane J.L. Tian S. Nie J. Jonsdottir G.A. Ruotti V. Stewart R. et al.Science. 2007; 318: 1917-1920Crossref PubMed Scopus (7581) Google Scholar). Various strategies have been developed to generate iPSCs with fewer or no exogenous genetic manipulations, which represent a major hurdle for iPSC applications (Yamanaka, 2009Yamanaka S. Cell. 2009; 137: 13-17Abstract Full Text Full Text PDF PubMed Scopus (552) Google Scholar). With the ultimate goal of generating iPSCs with a defined small molecule cocktail alone, substantial effort and progress have been made in identifying chemical compounds that can functionally replace exogenous reprogramming TFs and/or enhance the efficiency and kinetics of reprogramming (Shi et al., 2008Shi Y. Desponts C. Do J.T. Hahm H.S. Schöler H.R. Ding S. Cell Stem Cell. 2008; 3: 568-574Abstract Full Text Full Text PDF PubMed Scopus (690) Google Scholar, Huangfu et al., 2008Huangfu D. Osafune K. Maehr R. Guo W. Eijkelenboom A. Chen S. Muhlestein W. Melton D.A. Nat. Biotechnol. 2008; 26: 1269-1275Crossref PubMed Scopus (1070) Google Scholar, Lyssiotis et al., 2009Lyssiotis C.A. Foreman R.K. Staerk J. Garcia M. Mathur D. Markoulaki S. Hanna J. Lairson L.L. Charette B.D. Bouchez L.C. et al.Proc. Natl. Acad. Sci. USA. 2009; 106: 8912-8917Crossref PubMed Scopus (313) Google Scholar, Ichida et al., 2009Ichida J.K. Blanchard J. Lam K. Son E.Y. Chung J.E. Egli D. Loh K.M. Carter A.C. Di Giorgio F.P. Koszka K. et al.Cell Stem Cell. 2009; 5: 491-503Abstract Full Text Full Text PDF PubMed Scopus (610) Google Scholar, Maherali and Hochedlinger, 2009Maherali N. Hochedlinger K. Curr. Biol. 2009; 19: 1718-1723Abstract Full Text Full Text PDF PubMed Scopus (279) Google Scholar, Lin et al., 2009Lin T. Ambasudhan R. Yuan X. Li W. Hilcove S. Abujarour R. Lin X. Hahm H.S. Hao E. Hayek A. Ding S. Nat. Methods. 2009; 6: 805-808Crossref PubMed Scopus (461) Google Scholar, Li et al., 2009Li W. Zhou H. Abujarour R. Zhu S. Young Joo J. Lin T. Hao E. Schöler H.R. Hayek A. Ding S. Stem Cells. 2009; 27: 2992-3000PubMed Google Scholar, Esteban et al., 2010Esteban M.A. Wang T. Qin B. Yang J. Qin D. Cai J. Li W. Weng Z. Chen J. Ni S. et al.Cell Stem Cell. 2010; 6: 71-79Abstract Full Text Full Text PDF PubMed Scopus (734) Google Scholar). To date, only neural stem cells (NSCs), which endogenously express SOX2 and cMYC at a high level, have been reprogrammed to iPSCs by exogenous expression of just OCT4 (Kim et al., 2009Kim J.B. Greber B. Araúzo-Bravo M.J. Meyer J. Park K.I. Zaehres H. Schöler H.R. Nature. 2009; 461 (649–3)Google Scholar). However, human fetal NSCs are rare and difficult to obtain. It is therefore important to develop reprogramming conditions for other more accessible somatic cells. Here we report a small molecule cocktail that enables reprogramming of human primary somatic cells to iPSCs with exogenous expression of only OCT4. In addition, mechanistic studies revealed that modulation of cell metabolism from mitochondrial oxidation to glycolysis plays an important role in reprogramming. Among several readily available primary human somatic cell types, keratinocytes can be isolated easily from human skin or hair follicle, and therefore represent an attractive cell source for reprogramming. Keratinocytes also endogenously express KLF4 and cMYC, and can be reprogrammed efficiently using the conventional four TFs or three TFs (without cMYC) (Aasen et al., 2008Aasen T. Raya A. Barrero M.J. Garreta E. Consiglio A. Gonzalez F. Vassena R. Bilić J. Pekarik V. Tiscornia G. et al.Nat. Biotechnol. 2008; 26: 1276-1284Crossref PubMed Scopus (1066) Google Scholar, Maherali et al., 2008Maherali N. Ahfeldt T. Rigamonti A. Utikal J. Cowan C. Hochedlinger K. Cell Stem Cell. 2008; 3: 340-345Abstract Full Text Full Text PDF PubMed Scopus (428) Google Scholar). More recently, we reported that dual inhibition of TGFβ and MAPK/ERK pathways using small molecules (SB431542 and PD0325901, respectively) provided significantly enhanced conditions for reprogramming of human fibroblasts with the four TFs (i.e., OSKM) (Lin et al., 2009Lin T. Ambasudhan R. Yuan X. Li W. Hilcove S. Abujarour R. Lin X. Hahm H.S. Hao E. Hayek A. Ding S. Nat. Methods. 2009; 6: 805-808Crossref PubMed Scopus (461) Google Scholar). We have also shown that this dual pathway inhibition can also enhance reprogramming of human keratinocytes by two exogenous TFs (i.e., OK) with two small molecules, Parnate (an inhibitor of lysine-specific demethylase 1) and CHIR99021 (a GSK3 inhibitor) (Li et al., 2009Li W. Zhou H. Abujarour R. Zhu S. Young Joo J. Lin T. Hao E. Schöler H.R. Hayek A. Ding S. Stem Cells. 2009; 27: 2992-3000PubMed Google Scholar). With a goal of OCT4-only reprogramming, we developed a stepwise strategy for refining reprogramming conditions and identifying additional small molecules that enhance reprogramming. We first attempted to further optimize the reprogramming process using four or three TFs (i.e., OSKM or OSK) in neonatal human epidermal keratinocytes (NHEKs) by testing various inhibitors of TGFβ and MAPK pathways at different concentrations using previously reported human iPSC characterization methods (Lin et al., 2009Lin T. Ambasudhan R. Yuan X. Li W. Hilcove S. Abujarour R. Lin X. Hahm H.S. Hao E. Hayek A. Ding S. Nat. Methods. 2009; 6: 805-808Crossref PubMed Scopus (461) Google Scholar). Encouragingly, we found that the combination of 0.5 μM A-83-01 (a more potent and selective TGFβ receptor inhibitor) and 0.5 μM PD0325901 was more effective than previous small molecule combinations at enhancing reprogramming of human keratinocytes transduced with OSKM or OSK (Figure 1A ). Remarkably, when we reduced the viral transduction to only two factors (OK), we could still generate iPSCs from NHEKs when they were treated with 0.5 μM A-83-01 and 0.5 μM PD0325901, although with low efficiency. We then began screening additional small molecules from a collection of known bioactive compounds at various concentrations as previously reported (Shi et al., 2008Shi Y. Desponts C. Do J.T. Hahm H.S. Schöler H.R. Ding S. Cell Stem Cell. 2008; 3: 568-574Abstract Full Text Full Text PDF PubMed Scopus (690) Google Scholar). Among more than 50 compounds tested, we found that a small molecule activator of 3′-phosphoinositide-dependent kinase-1 (PDK1), PS48 (5 μM), which has not previously been reported to have reprogramming activity, can enhance reprogramming efficiency by about 15-fold. Interestingly, we also found that 0.25 mM sodium butyrate (NaB, a histone deacetylase inhibitor) is much more reliable and efficient than the previously reported 0.5 mM VPA for the generation of iPSCs under OK conditions (Figure 1B). Subsequent follow-up studies demonstrated that a combination of 5 μM PS48 and 0.25 mM NaB could further enhance the reprogramming efficiency over 25-fold (Figure 1B). With such high efficiency of reprogramming NHEKs with two TFs, we explored the possibility of generating iPSCs with OCT4 alone by refining combinations of these small molecules during different treatment windows. Primary NHEKs were transduced with OCT4 and treated with the chemicals. We found that small TRA-1-81-positive iPSC colonies resembling hESCs (four to six colonies out of 1,000,000 seeded cells) appeared in OCT4-infected NHEKs that were treated with 0.25 mM NaB, 5 μM PS48, and 0.5 μM A-83-01 during the first 4 weeks, followed by treatment with 0.25 mM NaB, 5 μM PS48, 0.5 μM A-83-01, and 0.5 μM PD0325901 for another 4 weeks. These TRA-1-81-positive iPSC colonies grew larger in conventional hESC culture media and could be serially passaged to yield stable iPSC clones that were characterized further. We also found that OCT4-only iPSCs could be generated from adult human epidermal keratinocytes (AHEKs) by addition of 2 μM Parnate and 3 μM CHIR99021 (which had been shown to improve reprogramming of NHEKs under OK condition) to this chemical cocktail (Table S1 available online). After this successful reprogramming of primary human keratinocytes to iPSCs by OCT4 and small molecules, we applied the same conditions to other human primary cell types, including human umbilical vein endothelial cells (HUVECs) and amniotic fluid-derived cells (AFDCs). Likewise, TRA-1-81-positive iPSC colonies appeared in OCT4-infected HUVECs and AFDCs that were treated with chemicals for 5–6 weeks. Remarkably, reprogramming of HUVECs and AFDCs was more efficient and faster than reprogramming of NHEKs using the OCT4 and small molecules protocol (Table S1). Finally, two clones of iPSC-O cells from each cell type were expanded for over 20 passages under conventional hESC culture condition and characterized further (Table S2). The stably expanded hiPSC-O cells were morphologically indistinguishable from hESCs, stained positive for alkaline phosphatase (ALP), and expressed typical pluripotency markers, including OCT4, SOX2, NANOG, TRA-1-81, and SSEA4, as detected by immunocytochemistry (ICC) (Figures 1C, S1A, S1C, and data not shown). In addition, RT-PCR analysis confirmed the expression of the endogenous human OCT4, SOX2, NANOG, REX1, UTF1, TDGF2, and FGF4 genes, and the silencing of exogenous OCT4 (Figure S2A available online). Furthermore, bisulfite sequencing analysis revealed that the OCT4 and NANOG promoters of hiPSC-O cells are largely demethylated, providing further evidence for reactivation of the pluripotency transcription program in these cells (Figure 1D). Global gene expression analysis of hiPSC-O cells, NHEKs, and hESCs showed that hiPSC-O cells are distinct from NHEKs (Pearson correlation value: 0.87) and most similar to hESCs (Pearson correlation value: 0.98) (Figure 1E). Genotyping analysis showed that hiPSC-O cells only contained the OCT4 transgene without the contamination of transgenes KLF4 or SOX2 (Figure S2B). Karyotyping results demonstrated that hiPSC-O maintained a normal karyotype during the whole reprogramming and expansion process (Figure S2C), and DNA fingerprinting tests excluded the possibility that they arose from hESC contamination in the laboratory (Figure S2D). To examine the developmental potential of the hiPSC-O cells, they were differentiated in vitro using a standard embryoid body (EB) differentiation approach. ICC analyses demonstrated that the hiPSC-O cells could effectively differentiate into characteristic βIII-tubulin+ neuronal cells (ectoderm), SMA+ mesodermal cells, and AFP+ endodermal cells (Figures 1F, S1B, and S1D). Quantitative PCR analyses further confirmed the expression of these and additional lineage-specific marker genes characteristic of ectodermal (βIII-tubulin and NESTIN), mesodermal (MSX1 and MLC2a), and endodermal (FOXA2 and AFP) cells (data not shown). After the EB protocol, the hiPSC-O cells could also give rise to rhythmically beating cardiomyocytes (Movie S1 available online). To test the in vivo pluripotency of the cells, they were transplanted into SCID mice. After 4–6 weeks, the hiPSC-O cells effectively generated typical teratomas containing derivatives of all three germ layers (Figure 1G). Collectively, these in vitro and in vivo characterizations demonstrated that a single transcription factor, OCT4, combined with a defined small molecule cocktail is sufficient to reprogram several human primary somatic cell types to iPSCs that are morphologically, molecularly, and functionally similar to pluripotent hESCs. We then investigated the molecular mechanism of action of the PDK1 activator PS48 in enhancing reprogramming. It has been shown that differentiated somatic cells typically use mitochondrial oxidation while pluripotent cells mainly use glycolysis for cell proliferation (Manning and Cantley, 2007Manning B.D. Cantley L.C. Cell. 2007; 129: 1261-1274Abstract Full Text Full Text PDF PubMed Scopus (4269) Google Scholar, Kondoh et al., 2007Kondoh H. Lleonart M.E. Nakashima Y. Yokode M. Tanaka M. Bernard D. Gil J. Beach D. Antioxid. Redox Signal. 2007; 9: 293-299Crossref PubMed Scopus (239) Google Scholar, Vander Heiden et al., 2009Vander Heiden M.G. Cantley L.C. Thompson C.B. Science. 2009; 324: 1029-1033Crossref PubMed Scopus (8527) Google Scholar, Prigione et al., 2010Prigione A. Fauler B. Lurz R. Lehrach H. Adjaye J. Stem Cells. 2010; 28: 721-733Crossref PubMed Scopus (449) Google Scholar). Therefore, generation of iPSCs would appear to involve metabolic reprogramming from mitochondrial oxidation to glycolysis. Differential use of glycolytic metabolism over mitochondrial oxidation by pluripotent cells would favor pluripotency by promoting proliferation/cell cycle transitions with less oxidative stress. In addition, in highly proliferating cells oxidative phosphorylation would not be able to meet the demand of providing macromolecular precursors for cell replication, and would also generate a significant amount of reactive oxygen species that could induce excessive oxidative damages. On the other hand, glycolytic metabolism could more effectively generate macromolecular precursors, such as glycolytic intermediates for nonessential amino acids and acetyl-CoA for fatty acids, while providing sufficient energy to meet the needs of proliferating cells (Kondoh et al., 2007Kondoh H. Lleonart M.E. Nakashima Y. Yokode M. Tanaka M. Bernard D. Gil J. Beach D. Antioxid. Redox Signal. 2007; 9: 293-299Crossref PubMed Scopus (239) Google Scholar, Vander Heiden et al., 2009Vander Heiden M.G. Cantley L.C. Thompson C.B. Science. 2009; 324: 1029-1033Crossref PubMed Scopus (8527) Google Scholar). In addition, growth factor signaling pathways-AKT activation, hypoxic conditions/HIF-1α, and the reprogramming factor MYC all regulate various aspects of cellular metabolism, including the upregulation of glucose transporters and metabolic enzymes of glycolysis, such as GLUT1, HK2, and PFK1 (Gordan et al., 2007Gordan J.D. Thompson C.B. Simon M.C. Cancer Cell. 2007; 12: 108-113Abstract Full Text Full Text PDF PubMed Scopus (543) Google Scholar, DeBerardinis et al., 2008DeBerardinis R.J. Lum J.J. Hatzivassiliou G. Thompson C.B. Cell Metab. 2008; 7: 11-20Abstract Full Text Full Text PDF PubMed Scopus (2533) Google Scholar). Interestingly, a hypoxic environment and its effector, HIF-1α activation, both of which have been closely linked to promoting glycolytic metabolism, were reported to improve reprogramming efficiency for both mouse and human cells (Yoshida et al., 2009Yoshida Y. Takahashi K. Okita K. Ichisaka T. Yamanaka S. Cell Stem Cell. 2009; 5: 237-241Abstract Full Text Full Text PDF PubMed Scopus (566) Google Scholar). Moreover, MYC expression/activity was also shown to play an essential role in promoting glycolytic metabolism and promoting reprogramming efficiency (Vander Heiden et al., 2009Vander Heiden M.G. Cantley L.C. Thompson C.B. Science. 2009; 324: 1029-1033Crossref PubMed Scopus (8527) Google Scholar). Together, these studies suggested that one potential mechanism of MYC, hypoxic condition/HIF-1α, and growth factor/AKT pathway activation in enhancing reprogramming could involve converging on an essential role in regulating glycolytic metabolism. Because PS48 is an allosteric small molecule activator of PDK1 that can lead to downstream AKT activation (Hindie et al., 2009Hindie V. Stroba A. Zhang H. Lopez-Garcia L.A. Idrissova L. Zeuzem S. Hirschberg D. Schaeffer F. Jørgensen T.J.D. Engel M. et al.Nat. Chem. Biol. 2009; 5: 758-764Crossref PubMed Scopus (107) Google Scholar), we hypothesized that PS48 may facilitate a metabolic conversion from mitochondrial oxidation to glycolysis during the reprogramming process, as discussed above. Supporting this notion, we found that treatment with PS48 activated downstream AKT/PKB (Figure 2A ), upregulated expression of several key glycolytic genes (Figure 2D), and consequently enhanced glycolysis as measured by increased lactate production (Figure 2E). The effects of PS48 on promoting reprogramming and conversion to glycolysis could be blocked by either a specific PDK1 inhibitor (UCN-01) or a specific glycolysis inhibitor (2-Deoxy-D-glucose, or 2-DG) (Figures 2B and 2E). Consistently, we also found that UCN-01 inhibited glycolytic gene expression in NHEKs (Figure 2D), and either UCN-01 or 2-DG on their own blocked the reprogramming process (Figure 2C). Importantly, and consistent with the idea that somatic cells differentially use mitochondrial oxidation for cell proliferation, inhibition of glycolysis by 2-DG did not affect somatic cell proliferation (Figure 2F). This result ruled out the possibility that the glycolysis inhibitor's effect on reprogramming results from an effect on cell growth/viability. In addition, a time course study on glycolysis modulators' effect on reprogramming revealed that only 8 day treatment with these glycolysis modulators was sufficient to affect reprogramming efficiency (Figure 2C). This finding suggests that early steps in the reprogramming process were affected by these specific glycolysis modulators because there were no iPSCs generated at this time point (8 days). Moreover, several known small molecules that have been widely used to modulate mitochondrial oxidation (2,4-dinitrophenol), glycolytic metabolism (Fructose 2,6-bisphosphate and oxalate), or more specifically HIF pathway activation (N-oxaloylglycine and Quercetin) also showed corresponding effects on reprogramming: i.e., compounds that promote glycolytic metabolism enhance reprogramming (such as 2,4-dinitrophenol and N-oxaloylglycine), whereas compounds that block glycolytic metabolism inhibit reprogramming (such as oxalate) (Figure 2G) (Hewitson and Schofield, 2004Hewitson K.S. Schofield C.J. Drug Discov. Today. 2004; 9: 704-711Crossref PubMed Scopus (137) Google Scholar, Pelicano et al., 2006Pelicano H. Martin D.S. Xu R.H. Huang P. Oncogene. 2006; 25: 4633-4646Crossref PubMed Scopus (1009) Google Scholar). In conclusion, these results collectively indicated that a metabolic switch to anaerobic glycolysis is an important step in reprogramming somatic cells to pluripotent stem cells. These studies have a number of important implications: (1) although human fetal NSCs were previously reprogrammed to iPSCs by ectopic expression of OCT4 alone, our study now shows that iPSCs can be derived from readily available primary human somatic cells (e.g., keratinocytes) transduced with a single exogenous reprogramming gene, OCT4. (2) The identification of small molecule cocktail that we used, which functionally replaces three master TFs all together (i.e., SOX2, KLF4, and MYC) in enabling the generation of iPSCs with OCT4 alone, represents an additional step toward the overall goal of reprogramming with only small molecules. (3) One way in which PS48 enhances reprogramming appears to be facilitating the metabolic conversion from mitochondrial oxidation, which is mainly used by adult somatic cells, to glycolysis, which is mainly used by pluripotent cells. Modulation of cellular metabolism by small molecules to either enhance reprogramming or inhibit pluripotent cell proliferation may well have additional applications in the future development of iPSC technology. S.D. is supported by funding from Fate Therapeutics, California Institute for Regenerative Medicine, NICHD, NHLBI, NIMH/NIH, Prostate Cancer Foundation, Esther B. O'Keeffe Foundation, and The Scripps Research Institute. K.Z. is supported by grants from National Eye Institute/National Institute of Health, VA Merit Award, the Macula Vision Research Foundation, Research to Prevent Blindness, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and Dick and Carol Hertzberg Fund. We thank all the members of the Ding lab for helpful discussions. We also thank Xiaolei Wang and Chao Zhao of the Zhang lab for technical assistances. The GEO accession number is GSE25218 for our microarray data in this manuscript. Download .pdf (1.5 MB) Help with pdf files Document S1. Supplemental Figures, Supplemental Tables, and Supplemental Experimental Procedures Download .avi (4.03 MB) Help with avi files Movie S1. Rhythmically Beating Cardiomyocytes from hiPSC-O Cells after Application of Embryoid Body Differentiation Approach

Abstract:Biophysical cues — in the form of insoluble signals from adhesive, mechanical or topological cues — can be important driving forces in embryonic development, adult tissue homeostasis and disease1. For example, randomization of left–right embryonic patterning caused by defects in the primary cilium (an antenna-like sensory organelle), hypertrophic cardiomyopathy induced by pressure overload (from hypertension, for instance) and cell invasion induced by deregulated remodelling of the extracellular matrix in cancer2, all involve cellular responses to biomechanical cues. Growing evidence also shows that biophysical cues help control the fate of adult stem cells and embryonic stem cells (ESCs). In fact, matrices mimicking the stiffness of brain, muscle or bone induce human mesenchymal stromal cells (MSCs) to differentiate, in identical media conditions, into the corresponding specialized cell types3. Also, the outcomes of human MSC and ESC differentiation can be influenced by modifying the lateral spacing of adhesion peptides4 or by controlling colony size5, respectively. However, except for the production of induced pluripotent stem cells (iPSCs) in stirred suspension culture6 and the role of extracellular collagen in mediating fibroblast reprogramming7, little is known about the effects of biophysical cues on cell reprogramming. Writing in Nature Materials, Song Li and colleagues demonstrate that iPSC generation by exogenous transcription factors can be significantly enhanced by seeding mouse or human fibroblasts onto polymer substrates with parallel microgrooves or onto aligned nanofibrous polymer scaffolds8. The researchers also show that the micro- and nanopatterned substrates increase the expression of epithelial and pluripotency genes by inducing the cells to acquire a more elongated shape, which through the mediation of mechanical signals transmitted by the cytoskeleton affects the acetylation and methylation patterns of the DNA-packaging histones. Cell reprogramming has been traditionally viewed as a slow and inefficient multistep process in which cells must overcome a series of barriers to reach an ESC-like pluripotent state9. This is not surprising, because the organization of chromatin in somatic cells is more compact than in ESCs, and thus a significant degree of unwinding is necessary to produce iPSCs9. One of the first noticeable check points in this course is a mesenchymal-to-epithelial transition (MET), which coincides with the loss of somatic-cell characteristics and precedes the activation of pluripotency genes10. Epigenetic regulators — in particular histone deacetylases (HDACs), demethylases and methyltransferases — exert very tight control over the MET phase of reprogramming and the subsequent events9. Interestingly, Li and co-authors show that patterned surfaces enhance reprogramming in part by reducing the expression of HDAC2 and increasing that of the WD repeat domain 5 (WDR5) — a core subunit of histone methyltransferase protein complexes8 (Fig. 1). HDAC2 is a barrier for microRNA-based reprogramming11, and HDAC inhibitors (including valproic acid; VPA) are among the most potent reprogramming promoters12. Conversely, WDR5 is an essential regulator of the ESC pluripotency network and is required for reprogramming13. A decrease in the expression of HDAC2 and an increase in that of WDR5 result in both increased histone 3 (H3) acetylation and H3 lysine 4 (K4) di- or trimethylation on epithelial gene promoters (for example, E-cadherin) as well as on pluripotency gene promoters (such as Oct4, Sox2 and Nanog), allowing a more efficient transition to pluripotency8. Consequently, growing somatic cells on surfaces with micro- or nanotopographical features mimics the potentiating effects on reprogramming of VPA or lysine demethylase inhibitors that promote H3 acetylation and H3K4 methylation, respectively. Interestingly, such epigenetic modifications (in particular the gain of acetylated H3) correlate with those triggered by mechanical stress in other settings (such as in MSCs or vascular cells1), suggesting that the application of external forces on cells grown on standard surfaces has similar consequences. Yet, our understanding of how mechanical signals affect histone methylation and acetylation patterns during reprogramming remains far from complete. For example, how cell elongation changes the expression of HDAC2 and WDR5 is unknown. Li and colleagues used blebbistatin (an inhibitor of actomyosin contractility) to show that the cytoskeleton is involved8. Still, further work will be needed to find out whether the cytoskeleton modulates gene expression and reprogramming indirectly through intracellular pathways (such as TGF-β signalling1), or if there is a direct chromatin effect that arises as a result of changes in nuclear shape (which most often correlates with cell shape). If the mechanotransduction mechanism turns out to be direct, it could be initiated genome-wide or triggered by specialized nuclear mechanosensitive switches (such as the exogenous transcription factors used for reprogramming). Although it is unclear whether substrate-enhanced cell reprogramming is a general phenomenon (Li and co-authors only examined fibroblasts, and in the case of epithelial cells, cell stretching on micropatterned substrates may change their characteristics and prevent reprogramming), their work opens the door to studying the potentially synergistic effects of the substrate's rheological and surface properties on cell reprogramming. The latter could be tuned by coating substrates with different extracellular-matrix proteins. Also, it will be imperative to test whether the modified substrates influence iPSC quality, which would require tetraploid complementation experiments (for mouse iPSCs) and comprehensive genomic analysis (of copy number variations and point mutations, for instance)9. Still, although long-term safety of any human iPSC-derived products can only be truly assessed by government-regulated human clinical trials after extensive in vitro and animal experimentation, it is reasonable to suggest that the passive modification of surfaces to improve reprogramming efficiency may be safer than the use of chemical compounds such as VPA. Moreover, complementing recent discoveries on near-100% reprogramming efficiency14 and pure chemical reprogramming15, Li and colleagues' work reinforces the general idea that biophysical cues play a fundamental role in changing the identity of cells, and highlights the importance of optimizing both biophysical and biochemical parameters of differentiation protocols to emulate the native cell environment. Biophysical cues could also be selectively employed for improving the generation of specific cell lineages by means of transdifferentiation. In addition to being key to in vitro experimentation, specifically optimized biomaterials may also enhance cell fate conversions in vivo. Overall, hybrid approaches combining chemicals (without exogenous factors) and appropriately patterned cell-growth substrates might allow efficient cell fate conversions (reprogramming, differentiation and transdifferentiation) both in vitro and in vivo. Download references

N-Cadherin Nanoantagonist Driven Mesenchymal-to-Epithelial Transition in Fibroblasts for Improving Reprogramming Efficiency

Efficient reprogramming of human fibroblasts using RNA reprogramming with DAPT and iDOT1L under normoxia conditions

Direct Reprogramming of Mouse Fibroblasts to Neural Progenitors

Brief Report: Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts

High-Efficiency Cellular Reprogramming by Nanoscale Puncturing

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Direct Reprogramming of Adult Human Fibroblasts to Functional Neurons under Defined Conditions.

Acceleration of Mesenchymal-to-Epithelial Transition (MET) during Direct Reprogramming Using Natural Compounds

Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation

Reprogramming of human primary somatic cells by OCT4 and chemical compounds.

E-Cadherin-Mediated Cell-Cell Contact is Critical for Induced Pluripotent Stem Cell Generation

Unlocking cellular plasticity: Enhancing human iPSC reprogramming through bromodomain inhibition and extracellular matrix gene expression regulation

Efficient feeder-free episomal reprogramming with small molecules

A combined epigenetic and non-genetic approach for reprogramming human somatic cells

NAC1 Regulates Somatic Cell Reprogramming by Controlling Zeb1 and E-cadherin Expression.

MicroRNA Replacing Oncogenic Klf4 and C-Myc for Generating Ips Cells Via Cationized Pleurotus Eryngii Polysaccharide-based Nanotransfection.

Reprogramming of mouse fibroblasts to an intermediate state of differentiation by chemical induction.

Cell reprogramming: Into the groove.

A small-molecule approach towards the Fountain of Youth: chemically induced pluripotent stem cells

High-efficiency Generation of Induced Pluripotent Mesenchymal Stem Cells from Human Dermal Fibroblasts Using Recombinant Proteins

A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts.